SEABELIFE
SeaBeLife is a biotechnology company that develops a range of drug candidates intended to block regulated necrosis (or regulated cell death of cells), from a family of patented molecules.
SEABELIFE
Industry:
Biotechnology Medical
Founded:
2019-01-01
Address:
Roscoff, Bretagne, France
Country:
France
Website Url:
http://www.seabelife.com
Total Employee:
1+
Status:
Active
Contact:
+33(0)2 98 29 23 48
Total Funding:
3.87 M EUR
Similar Organizations
NMD Pharma
NMD Pharma is a small molecule drug discovery company that develops novel treatments of neuromuscular disorders.
Novellus
Novellus is a biotechnology company working to develop engineered cellular medicines.
Remix Therapeutics
Remix Therapeutics is a biotechnology company.
Theolytics
Theolytics is a pre-clinical stage biotechnology company developing next-generation oncolytic viral therapies.
VectivBio
VectivBio is a biotechnology company committed to making innovative treatments for patients suffering from serious rare diseases.
Current Employees Featured
Morgane Rousselot Founder, President, and CEO @ SeaBeLife
Founder, President, and CEO
Claire Delehouze CTO @ SeaBeLife
CTO
Founder
Investors List
Bpifrance
Bpifrance investment in Grant - SeaBeLife
Ava capital
Ava capital investment in Seed Round - SeaBeLife
Bpifrance
Bpifrance investment in Seed Round - SeaBeLife
Angels Santé
Angels Santé investment in Seed Round - SeaBeLife
Official Site Inspections
http://www.seabelife.com
- Host name: web1.anaximandre.com
- IP address: 87.98.151.65
- Location: France
- Latitude: 48.8582
- Longitude: 2.3387
- Timezone: Europe/Paris
More informations about "SeaBeLife"
Seabelife – Sea inspired and life oriented biotech
SeaBeLife cible en priorité les pathologies aigües et orphelines (ou rares), avec un traitement unique ou court. Notre objectif est double : faciliter le développement clinique pour apporter …See details»
Seabelife – Sea inspired and life oriented biotech
SeaBeLife is a biotechnology company developing two families of patented candidate molecules designed to block regulated necrosis – also known as …See details»
SeaBeLife - Crunchbase Company Profile & Funding
Organization. SeaBeLife . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. ... SeaBeLife is a biotechnology company that …See details»
Management – Seabelife
SeaBeLife receives close to €1.4M deep tech financing from Bpifrance SeaBeLife Biotech raises € 1 million to carry onits drug developments targeting regulated cell death A biotech company …See details»
SeaBeLife - Funding, Financials, Valuation & Investors - Crunchbase
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors ... SeaBeLife . 1: obfuscated. …See details»
SeaBeLife Biotech - LinkedIn
SeaBeLife dans la presse / SeaBeLife cherche 8 millions d’euros d’ici début 2025 Un bel article paru dans BiotechFinances - Medtech - Santé Numérique - DTx - Intelligence Artificielle sur l ...See details»
Omnigen Biodata - Crunchbase Company Profile
Organization. Omnigen Biodata . Connect to CRM . Save . Summary. People. Technology. Signals & News. Similar Companies. ... Alternatives and possible competitors to Omnigen Biodata may include SeaBeLife, Ascelia Pharma, and …See details»
SeaBeLife Biotech - healthtechinnovationdays6.com
SeaBeLife is pioneering a first-in-class approach to preventing organ failure by targeting dual inhibition of necroptosis and ferroptosis, pathways involved in severe liver and retinal …See details»
SeaBeLife receives Orphan Drug Designation (ODD) from EMA for …
Sep 3, 2024 SeaBeLife’s approach – based on dual action molecules that simultaneously target two different pathological cell death pathways – is unique in tackling the complex crosstalk …See details»
SeaBeLife Company Profile: Overview and Full News Analysis
SeaBeLife, a biotechnology company developing drug candidates to block cellular necrosis, today announces the award of more than 1.5M ($1.6M) in financing for its SeaBeEYE project at the i …See details»
SeaBeLife - Tech Stack, Apps, Patents & Trademarks - Crunchbase
Nov 1, 2024 SeaBeLife is a biotechnology company that develops a range of drug candidates.See details»
SeaBeLife - EU-Startups
SeaBeLife’s technology centres around a portfolio of more than 45 biologically-active relevant molecules and the company has filed four patents to protect the applications of these …See details»
SeaBeLife Biotech - VentureRadar
SeaBeLife is a biotechnology company that is currently developing families of patented candidate molecules designed to block regulated necrosis (that is, regulated cell death). SeaBeLife …See details»
SeaBeLife receives close to €1.4M deep tech financing from …
Mar 14, 2022 Funds will enable SeaBeLife to develop pipeline of innovative molecules intended to block programmed cell death in cases of acute liver and kidney disease Roscoff, France, …See details»
SeaBeLife - Contacts, Employees, Board Members, Advisors
SeaBeLife is a biotechnology company that develops a range of drug candidates.See details»
News – Seabelife
Dec 8, 2023 SeaBeLife Biotech raises € 1.5 million to develop drugs targeting regulated cell death. Roscoff, June 15, 2020. SeaBeLife, a pharmaceutical … Lire la suite. Categories Press …See details»
Brittany-based biotech startup SeaBeLife picks up €1.4 million
Mar 14, 2022 Founded in 2019, SeaBeLife is a biotech startup developing drug candidates to block cell necrosis. Today, it’s announced a funding boost of almost €1.4 million financing from …See details»
SeaBeLife Biotech raises € 1 million to carry onits drug …
May 28, 2021 SeaBeLife, a pharmaceutical company focused on identifying a new class of drug candidates able to deprogram regulated cell death, announces its second seed money …See details»
SeaBeLife awarded over €1.5 million in i-Nov innovation competition
Apr 22, 2024 SeaBeLife currently employs eight people and since its creation has raised €5.5M ($5.86M) in private equity and grants. In 2023, the company raised €1.2M ($1.28M) in …See details»
News – Seabelife
Sep 3, 2024 SeaBeLife raises €1.2 M ($1.28 M) from iXLife fund and historical investors SeaBeLife receives close to €1.4M deep tech financing from Bpifrance A biotech company …See details»